Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026
Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026
Company Drug

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine

Fineline Cube Nov 5, 2025

China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...

Company Deals

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash

Fineline Cube Nov 5, 2025

4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...

Company

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance

Fineline Cube Nov 5, 2025

Denmark‑based biopharma Novo Nordisk A/S (NYSE: NVO) disclosed Q1‑Q3 2025 financials that show a 15 %...

Policy / Regulatory

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs

Fineline Cube Nov 5, 2025

The China Center for Drug Evaluation (CDE) has released a draft list of the 100th...

Company Deals Drug

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma

Fineline Cube Nov 5, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...

Policy / Regulatory

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) has issued a formal notice to roll out the Silver‑Haired...

Policy / Regulatory

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) today released the Implementation Opinions on Promoting and Standardizing the...

Company Drug

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Fineline Cube Nov 5, 2025

Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Fineline Cube Nov 5, 2025

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...

Company Deals

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal

Fineline Cube Nov 5, 2025

Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...

Company Deals

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles

Fineline Cube Nov 4, 2025

Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...

Company Drug

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron

Fineline Cube Nov 4, 2025

Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...

Company

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes

Fineline Cube Nov 4, 2025

The Shanghai Pudong New Area Market Supervision Administration issued an administrative penalty against Green Valley...

Company Drug

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products

Fineline Cube Nov 4, 2025

China‑based CARsgen Therapeutics Holdings Limited (HKG: 2171) unveiled clinical data for two allogeneic CAR‑T candidates...

Policy / Regulatory

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption

Fineline Cube Nov 4, 2025

The Guangzhou Municipal Health Commission issued a comprehensive notice detailing twelve strategic measures aimed at...

Company Drug

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer

Fineline Cube Nov 4, 2025

China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...

Company Drug

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors

Fineline Cube Nov 4, 2025

China‑based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)...

Policy / Regulatory

NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale

Fineline Cube Nov 4, 2025

The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of...

Company Medical Device

Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic

Fineline Cube Nov 4, 2025

Amoy Diagnostics Co., Ltd. (“AmoyDx”) have secured approval from the China National Medical Products Administration...

Company Drug

GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa

Fineline Cube Nov 4, 2025

China‑based GenAns Biotechnology Co., Ltd. announced that its proprietary gene‑therapy drug GA001 injection received Fast‑Track...

Posts pagination

1 … 69 70 71 … 651

Recent updates

  • Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
  • Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
  • Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
  • Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
  • Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Company

Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.